Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy

Authors Danilova N, Kalzhanov Z, Nefedova N, Mal'kov P, Kosmas I, Eliseeva M, Mynbaev O

Received 7 November 2014

Accepted for publication 11 November 2014

Published 25 March 2015 Volume 2015:10(1) Pages 2417—2421

DOI https://doi.org/10.2147/IJN.S77186

Checked for plagiarism Yes

Editor who approved publication: Prof. Dr. Thomas J Webster


Natalia V Danilova,1,2 Zhomart R Kalzhanov,3 Nina A Nefedova,2 Pavel G Mal’kov,2 Ioannis P Kosmas,1,4 Marina Y Eliseeva,1,5 Ospan A Mynbaev1,5,6

1International Translational Medicine and Biomodeling Research Team, MIPT Center for Human Physiology, Laboratory of Cellular and Molecular Technologies, Moscow Institute of Physics and Technology, State University, 2Department of Physiology and Basic Pathology, Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia; 3Department of Human Metabolism, Academic Unit of Reproductive and Developmental Medicine, Sheffield University, Sheffield, UK; 4Department of Obstetrics and Gynecology, Ioannina State General Hospital G Chatzikosta, Ioannina, Greece; 5Department of Obstetrics, Gynecology and Reproductive Medicine, Peoples’ Friendship University of Russia, 6Laboratory of Immunology, Moscow State University of Medicine and Dentistry named after AI Evdokimov, Moscow, Russia
 
The long-term survival rate of patients with breast cancer was improved by the application of systemic adjuvant chemotherapy,1 although the primary breast cancer treatment strategy consists of mastectomy with lymphadenectomy and radiotherapy followed by breast reconstruction.2–5 Unfortunately, most adjuvant chemotherapeutic agents trigger major side effects.1,6 Therefore, we have read with great interest an article in the International Journal of Nanomedicine on the design of docetaxel-loaded solid lipid nanoparticles (DSNs) aimed at reducing the systemic toxicity of standardized docetaxel treatment.7
 
Read the original article 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]